Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Five Below Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Five Below Inc trades at $218.95 (market cap $11.75B). The key difference: Five Below Inc is far larger — about 4.1× Dyne Therapeutics Inc. Common Stock's market cap, and Five Below Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Five Below Inc for 46 Days on average.
| DYN | FIVE | |
|---|---|---|
Market Cap | $2.86B | $11.75B |
Volume | 3,341,579 | 742,657 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $262.72 |
52-Week Low | $14.60 | $147.05 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $2.18B | $12.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Five Below (FIVE) trades at $218.95, up 2.51% today, with strong earnings momentum after beating Q1 and Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with 40.26% gross margins and 28.25% ROE. Recent news highlights growth initiatives including a $600M buyback and digital marketing push. Revenue growth accelerated from $3.6B in 2024 to $3.9B in 2025, with projected $5.3B in 2026.
FIVE presents a growth opportunity with analyst consensus target of $298.44 (36% upside), though execution risks remain. The premium valuation (P/E 19.14) requires sustained margin expansion amid consumer spending pressures. Institutional sentiment is bullish with 60% buy ratings, but technical weakness near resistance at $219 suggests near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
